INTRODUCTION
MPNST is a rare soft tissue neoplasm that accounts for less than 10 % of all soft tissue sarcomas. 1 These tumors have a known association with neurofibromatosis type1 syndrome, an autosomal dominant disorder that involves NF-1 tumor suppressor gene, located on chromosome 17. 2 These tumors often originate in pre-existing neurofibromatosis type 1 lesions, affecting males between 20 to 50 years of age. These tumors have predilection for buttocks, thigh, brachial plexus, upper arm and paraspinal region. 2 MPNST spread perineurally by direct invasion or hematogenously to lungs followed by bone and finally pleura.
Lymph node metastasis is seen in less than 5% cases of all sarcomas and are often associated with epithelioid sarcoma, synovial sarcoma, rhabdomyosarcoma, clearcell sarcoma, and angiosarcoma. Lymph node metastasis is rare in MPNST and occurs in presence of widespread metastasis. 3 MPNST is treated by surgical excision and lymph node dissection is not routinely performed.
CASE REPORT
A 46-year-old male patient presented with progressively increasing, painful, left flank swelling of one year duration. He also complained of swellings in left axilla and groin for last six months. There was a steady unintentional significant weight loss but no jaundice, fever, bowel or urinary complaints. Patient had history of smaller swelling over same site which was excised two years back and diagnosed as neurofibroma on histological examination.
On examination, the patient weighted 60 kilos had multiple neurofibromas (Figure 1 ) all over his body along with café au lait spots and axillary freckling. He also had left axillary and inguinal lymphadenopathy. Mild pitting edema over the ankles and feet was recorded. A solitary, 15x12 cm, firm, bosselated, non-tender parietal mass extending between left costal margin and left iliac crest, from left anterior axillary line to left posterior scapular line was palpable, with overlying scar of previous surgery ( Figure 2 ). The mass had restricted mobility in all the planes and was also fixed to the skin in the region of the scar. No free fluid could be demonstrable. Liver, spleen and kidneys were not palpable. External genitalia were normal and systemic examination revealed left pleural effusion. Per-rectal examination was non-contributory. MRI abdomen revealed single 9.4x8.5x3cm multilobulated subcutaneous soft tissue mass suggestive of sarcoma, arising from left posterolateral abdominal wall muscles with necrotic areas (Figure 3 and 4) . There was also retroperitoneal lymphadenopathy in preaortic and para aortic regions, hepatomegaly and cholelithiasis without liver metastasis. There were multiple subcutaneous swellings. Other organs were normal. CECT chest revealed left pleural effusion but no lung metastasis. Bone scan also did not reveal any bony metastasis.
The patient was taken up for chemotherapy with alternating cycles of cyclophosphamide/doxorubicin and cisplatin/etoposide in view of metastatic tumor. Patient is doing well so far, pending further follow-up.
DISCUSSION
MPNST is a rare neoplasm accounting for less than 10% of all soft tissue sarcomas with an incidence of 0.1/100,000 per year. 1 A sarcoma is defined as MPNST when at least one of the following criteria is met:
 It arises from a peripheral nerve  It arises from a preexisting benign nerve sheath tumor (neurofibroma)  It demonstrates schwannoma cell differentiation on histologic examination.
These tumors have a known association with neurofibromatosis type 1 syndrome, an autosomal dominant disorder that involves NF-1 tumor suppressor gene, located on chromosome 17. It affects individuals between 20 to 50 years of age and can grow to giant sizes. These tumors often affect males, and often involving buttock, thigh, brachial plexus, upper arm and paraspinal region. Incidence of MPNST in patients with NF-1 is not exactly clear, varying from 2-29% in different literatures. 2 MPNST has been found to be associated with p53, p16 mutations, while NF1 gene activity does not independently cause MPNST. It can arise de-novo however; up to 60% MPNST originate in pre-existing neurofibromatosis type 1 lesions. Nerve of origin is not identifiable in upto 61% cases as documented by Nambisan et al. 4 The tumor spreads perineurally by direct invasion or hematogenously to lungs followed by bone and finally pleura. Definitive diagnosis requires tissue specimen in the form of FNAC, trucut biopsy or incisional biopsy, latter is recommended. Immunohistochemistry and electron microscopic studies are gradually replacing histopathology as confirmatory diagnostic methods, as these tumors display a wide variety of histological patterns and hence no absolute standard is accepted. 5 Studies by Matsunou et al have identified S-100 protein positivity and cytokeratin negativity as a supplementary tool for confirmation. The tumor is found to be S-100 positive in approximately 50-90% on immunohistochemistry. The treatment for MPNST has been combined modality that includes aggressive surgical excision or mass debulking with several cycles of adjuvant chemotherapy with cyclophosphamide/doxorubicin have been advocated. Adjuvant radiotherapy has also been investigated for treatment of advanced MPNST. For metastatic tumors chemotherapy is used as palliative therapy. Lymph node metastasis is rarely seen in patients with MPNST. 3 Very few cases exist in the literature that demonstrates lymph node metastasis in MPNST.
